The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Kirchgraber Paul R since 2020.
This trader's CIK number is 1791393.
At the time of last reporting, Kirchgraber Paul R was the CEO, Covance Drug Development of Laboratory Corp Of America Holdings. (stock ticker symbol LH).
Also see all insider trading activities at Laboratory Corp Of America Holdings.
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2023 | LH | 0 | $0 | 12,300 | $2,937,380 | 8,786 | $1,332,323 |
| 2022 | LH | 0 | $0 | 0 | $0 | 1,320 | $0 |
| 2021 | LH | 0 | $0 | 2,500 | $691,375 | 4,158 | $0 |
| 2020 | LH | 0 | $0 | 1,500 | $321,204 | 3,932 | $0 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2023-05-19 | LH | Option Ex | 4,300 | 182.51 | 784,793 |
| 2023-05-19 | LH | Sale | 4,300 | 216.91 | 932,708 |
| 2023-02-21 | LH | Sale | 8,000 | 250.58 | 2,004,672 |
| 2023-02-21 | LH | Option Ex | 3,000 | 182.51 | 547,530 |
| 2023-02-11 | LH | Option Ex | 483 | .00 | 0 |
| 2023-02-04 | LH | Option Ex | 560 | .00 | 0 |
| 2023-02-02 | LH | Option Ex | 443 | .00 | 0 |
| 2022-02-12 | LH | Option Ex | 317 | .00 | 0 |
| 2022-02-04 | LH | Option Ex | 560 | .00 | 0 |
| 2022-02-02 | LH | Option Ex | 443 | .00 | 0 |
| 2021-11-01 | LH | Option Ex | 2,007 | .00 | 0 |
| 2021-05-06 | LH | Sale | 2,500 | 276.55 | 691,375 |
| 2021-04-03 | LH | Option Ex | 1,010 | .00 | 0 |
| 2021-02-12 | LH | Option Ex | 581 | .00 | 0 |
| 2021-02-04 | LH | Option Ex | 560 | .00 | 0 |
| 2020-11-04 | LH | Sale | 1,500 | 214.14 | 321,204 |
| 2020-11-02 | LH | Option Ex | 2,006 | .00 | 0 |
| 2020-04-03 | LH | Option Ex | 1,010 | .00 | 0 |
| 2020-02-12 | LH | Option Ex | 579 | .00 | 0 |
| 2020-02-07 | LH | Option Ex | 337 | .00 | 0 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Kirchgraber Paul R (CEO, Covance Drug Development of Laboratory Corp Of America Holdings at the time of this reporting) see the Securities and Exchange Commission (SEC) website.